Antiproteinuric Efficacy of Losartan Potassium in Patients With Non-Diabetic Proteinuric Renal Diseases (0954-213)

Renal Disorder Clinical Trial

Official title:

A Randomized, Parallel, Double Blind Study of Losartan Versus Amlodipine in Patients With Mild to Moderate Hypertension and Chronic Nondiabetic Proteinuric Nephropathy: Evaluation of the Effect on Proteinuria and on the Plasmatic Levels of Growth Factors (TGFß and VEGF)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00140985
• Other study ID #: 0954-213
• Secondary ID: MK0954-2132005_0
• Status: Completed
• Phase: Phase 4
• Start date: February 2000
• Est. completion date: January 2002

Study information

• Verified date: February 2022
• Source: Organon and Co
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Antiproteinuric Efficacy of Losartan Potassium in Patients with Non-Diabetic Proteinuric Renal Diseases.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 97
• Est. completion date: January 2002
• Est. primary completion date: January 2002
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Males or females at least 18 years of age with non-diabetic proteinuric renal diseases

Related Conditions & MeSH terms

• Kidney Diseases
• Renal Disorder

Intervention

Drug:
• MK0954, losartan potassium/Duration of Treatment: 20 weeks

• Comparator: amlodipine / Duration of Treatment: 20 weeks

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Organon and Co

References & Publications (1)

Praga M, Andrade CF, Luño J, Arias M, Poveda R, Mora J, Prat MV, Rivera F, Galceran JM, Ara JM, Aguirre R, Bernis C, Marín R, Campistol JM. Antiproteinuric efficacy of losartan in comparison with amlodipine in non-diabetic proteinuric renal diseases: a do — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	24h proteinuria
Secondary	Changes in the plasma and urinary levels of TGF-beta